Molecular Partners AG(MOLN) - 2025 Q3 - Earnings Call Presentation

Extending the Boundaries of Targeted Cancer Therapies with Radio-DARPins and Next-Gen Immune Cell Engagers Q3 Financials October 30, 2025 Nasdaq, SIX Swiss Exchange: MOLN Disclaimer This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statem ...